Marker Therapeutics (MRKR) Free Cash Flow (2010 - 2026)
Marker Therapeutics (MRKR) reported Free Cash Flow of -$1.4 million for Q1 2026, up 74.47% year-over-year from -$804842.1 in Q1 2025, and up 26.1% quarter-over-quarter from -$1.9 million in Q4 2025.
Marker Therapeutics (MRKR) Free Cash Flow (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 17 years of Free Cash Flow data on file, last reported at -$1.4 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$1.4 million, up 74.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.9 million (up 37.02% YoY), and the FY2025 annual result was -$12.0 million, down 10.12% from the prior year.
- Free Cash Flow advanced to -$1.4 million in Q1 2026 per MRKR's latest filing, from -$1.9 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $4.9 million in Q3 2023 and troughed at -$14.6 million in Q1 2022.
- A 5-year average of -$4.0 million and a median of -$3.6 million in 2024 frame the typical range for Free Cash Flow.
- On a YoY basis, Free Cash Flow climbed as much as 192.4% in 2023 and fell as far as 514.67% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$9.5 million in 2022, then gained by 11.89% to -$8.4 million in 2023, then jumped by 44.03% to -$4.7 million in 2024, then jumped by 59.6% to -$1.9 million in 2025, then rose by 26.1% to -$1.4 million in 2026.
- Business Quant data shows MRKR's Free Cash Flow at -$1.4 million in Q1 2026, -$1.9 million in Q4 2025, and -$2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 63,220.27 |
| 10 | Marker Therapeutics | 27.04 Mn | 27.04 Mn | - | -1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -3.57 Mn |
| Jun 30, 2024 | -3.57 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | -8.40 Mn |
| Dec 31, 2023 | -8.40 Mn |